Diabetes
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kaga, T.
Right arrow Articles by Cheng, J.-T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kaga, T.
Right arrow Articles by Cheng, J.-T.
Social Bookmarking
Add to CiteULike   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?
Diabetes 50:1206-1210, 2001
© 2001 by the American Diabetes Association, Inc.

Modest Overexpression of Neuropeptide Y in the Brain Leads to Obesity After High-Sucrose Feeding

Toshihiro Kaga1, Akio Inui1, Minoru Okita1, Akihiro Asakawa1, Naohiko Ueno1, Masato Kasuga1, Mineko Fujimiya2, Noriyasu Nishimura3, Rika Dobashi3, Yasuo Morimoto4, I-Min Liu5, and Juei-Tang Cheng5

1 Second Department of Internal Medicine, Kobe University School of Medicine, Kobe
2 Department of Anatomy, Shiga University of Medical School, Otsu
3 Research & Development Division, Nippon Organon K.K.
4 Kampo & Healthcare Research Laboratories, Kanebo, Osaka, Japan
5 Department of Pharmacology, College of Medicine, National Cheng Kung University, Tainan, Taiwan, China


   ABSTRACT
TOP
 ABSTRACT
INTRODUCTION
 RESEARCH DESIGN AND METHODS
 REFERENCES
 
Neuropeptide Y (NPY), one of the most abundant peptide transmitters in the mammalian brain, is assumed to play an important role in feeding and body weight regulation. However, there is little genetic evidence that overexpression or knockout of the NPY gene leads to altered body weight regulation. Previously, we developed NPY-overexpressing mice by using the Thy-1 promoter, which restricts NPY expression strictly within neurons in the central nervous system, but we failed to observe the obese phenotype in the heterozygote. Here we report that in the homozygous mice, overexpression of NPY leads to an obese phenotype, but only after appropriate dietary exposure. NPY-overexpressing mice exhibited significantly increased body weight gain with transiently increased food intake after 50% sucrose–loaded diet, and later they developed hyperglycemia and hyperinsulinemia without altered glucose excursion during 1 year of our observation period.


   INTRODUCTION
TOP
 ABSTRACT
 INTRODUCTION
RESEARCH DESIGN AND METHODS
 REFERENCES
 
Neuropeptide Y (NPY) is a member of the peptide family, which includes the endocrine peptides, pancreatic polypeptide, and peptide YY. A significant body of literature argues that the arcuate nucleus NPY neurons are involved in energy homeostasis (12345). NPY potently stimulates food intake when introduced into the hypothalamus in the vicinity of the paraventricular nucleus and perifornical area (12345). NPY alters body temperature and peripheral energy metabolism and increases plasma insulin levels. Many syndromes of obesity in animals are characterized either by an increase in NPY levels in the hypothalamus or by an increase in NPY receptor abundance and sensitivity (3). When NPY was chronically administered into the ventricle or the hypothalamus, it was found to produce an obesity syndrome with salient features of hyperphagia, increased body weight, hyperinsulinemia, hypercorticosteronemia, muscle insulin resistance, and increased fat storage (6). However, because both NPY-overexpressing and knockout mice showed almost normal patterns of food intake and body weight (5,789), it is still an open question as to whether NPY has an essential role in increased body weight. Here we show that sucrose feeding renders seemingly normal NPY-overexpressing mice to exhibit part of the obesity syndrome.

NPY-overexpressing mice (homozygous) were developed by using the Thy-1 promoter, which localized transgene expression within the central nervous system (7). A modest overexpression of NPY was confirmed in these animals (Fig. 1), which were housed per group and examined in a less stressful condition than those housed individually. There were no apparent differences in body weight between NPY-overexpressing mice and their littermates when normal diet was provided. However, shortly after 50% sucrose was loaded on the diet, the homozygous mice became heavier than controls and maintained their increased body weight (Fig. 2A). This was accompanied by an increase in food intake that continued for several weeks after the high-sucrose feeding (Fig. 2B). The increased food intake in transgenic mice was significantly inhibited by the treatment with the NPY Y-1 receptor antagonist BIBO3304, but not the Y-5 receptor antagonist L-152,804 (Fig. 3). There was a significant difference in energetic efficiency, shown by a smaller decrease in body weight in response to 48-h fasting observed in transgenic mice compared with the control mice (13.4 ± 0.34 vs. 13.1 ± 0.96 and 8.11 ± 0.33 vs. 9.31 ± 0.41% body wt change at 0–24 h and 24–48 h, respectively; P < 0.05, n = 7). The mice did not show any change in oxygen consumption (7.07 ± 0.31 vs. 7.38 ± 0.39 and 5.33 ± 0.24 vs. 5.62 ± 0.38 ml/g body wt/h at 0–1 h and 1–2 h, respectively, for transgenic versus control mice; n = 9), which was determined with an O2/CO2 metabolism–measuring system at 25°C. NPY-overexpressing mice showed increased plasma levels of glucose and insulin (Figs. 1C and D), although they did not show impaired glucose tolerance after per os glucose loading (2 g/kg, area under curve [AUC] for glucose 369.0 ± 19.6 vs. 393.6 ± 35.8 mg · h · dl–1 for transgenic versus control mice; n = 9). The levels of total cholesterol and triglycerides did not differ appreciably between transgenic and control animals (not shown).



View larger version (15K):
[in this window]
[in a new window]
  		FIG. 1. Northern blot analysis in whole brain of NPY-overexpressing ({blacksquare}) and control ({square}) mice. A: Representative response. Expressions of mRNA for NPY, Y-1 receptor (Y-1), and Y-5 receptor (Y-5) were indicated using ß-actin as internal standard. B: Changes in mRNA. Statistical significance was determined by t test. Each group contained eight male mice.

 


View larger version (24K):
[in this window]
[in a new window]
  		FIG. 2. Obesity phenotype of transgenic mice (homozygous). A: Growth curve of NPY-overexpressing (•) and control ({circ}) mice fed on normal diet followed by 50% sucrose–loaded diet. The hatched bars show periods of food intake measurements. B: Cumulative food intake of NPY-overexpressing ({blacksquare}) and control ({square}) mice for 3 weeks as indicated in A. C and D: Plasma glucose (C) and insulin (D) levels of transgenic ({blacksquare}) and control ({square}) mice. Animals were housed per group under a 12-h light-dark cycle and had free access to food and water. Each group contained 8–10 male mice. *P < 0.05 and **P < 0.01 by t test (A, C, and D only). *P < 0.05 by Mann-Whitney U test; comparison was made on food consumed in each of the four dishes per week (B only).

 


View larger version (22K):
[in this window]
[in a new window]
  		FIG. 3. Effect of Y-1 receptor antagonist BIBO3304 (2 nmol/mouse every 12 h for 24 h) and Y-5 receptor antagonist L-152,804 (2 nmol/mouse every 12 h for 24 h) on food intake induced by 50% sucrose–loading in NPY-overexpressing mice. **P < 0.01 compared with the control group by analysis of variance followed by Bonferroni’s t test.

 
NPY mediates its effects through binding to the Y-type receptors, and the well-characterized effect on food intake may involve the Y-1 and Y-5 receptor subtypes (5,10). Both receptors are coupled to G proteins and are expressed in the brain, including the hypothalamus. The Y-5 receptor has pharmacological properties most closely matching a proposed feeding receptor (11). However, recent progress in the development of nonpeptide antagonists indicates that the Y-1 receptor mediates the appetite-stimulating effect of NPY (10). In the present study, the levels of Y-1 and Y-5 receptor mRNA expression were found to be affected in the brains of NPY-overexpressing mice, with a significant increase of Y-1 and a decrease of Y-5 receptor expression. Previous studies demonstrated that appetite evoked by either fasting or food restriction increased expression of Y-1 mRNA but did not increase Y-5 mRNA expression (3,12). A significant decrease of Y-5 receptor mRNA expression was found in the ventromedial, dorsomedial, and arcuate hypothalamic nuclei of the obese mouse brain using in situ hybridization (13). Downregulation of the Y-5 receptor in the obese Zucker rat was also demonstrated by competition binding assays (14). These results, together with a significant inhibition of food intake by Y-1 receptor antagonist in the present study, suggest a key role of the Y-1 receptor in the regulation of NPY-induced feeding. It may be possible that the modest overexpression of NPY modifies the balance between Y-1 and Y-5 receptors, resulting in a higher expression of Y-1 receptors.

Very recently, transgenic rats were generated by using the NPY genomic sequence (15). They exhibited behavioral insensitivity to stress and fear and impaired spatial learning, but they exhibited neither feeding nor body weight abnormalities, presumably because of the limited overexpression of NPY to areas outside those controlling feeding behaviors (15). Energy balance could be well maintained when NPY was removed or mildly overexpressed from early development of the nervous system (789). Moreover, mutant mice that lacked either the Y-1 or Y-5 receptor paradoxically developed obesity, despite the decrease in the effects of NPY and analogs on food intake (16,17). The unexpected phenotype of Y-1 and Y-5 knockouts developed later and was associated with decreased locomotor activity and increased food intake, respectively. In contrast, a recent study indicated an inhibitory role for the Y-2 receptor in the control of food intake and body weight. The Y-2 receptor–deficient mice developed obesity, especially when fed a high-fat diet (14). This may be in keeping with a presynaptic function for the Y-2 receptor in the hypothalamus (i.e., an inhibition of NPY release) (18), although Y-2 receptor agonists have the least effect on feeding when injected into the cerebral ventricle (10). As a whole, these studies present a complex picture for the role of NPY and its receptors in feeding and body weight regulation.

The present study provides direct genetic evidence that overexpression of NPY leads to obesity in the presence of a palatable diet, with increased food intake and energetic efficiency. The obesity phenotype in transgenic animals may be critically dependent on environmental (dietary) exposure. Previous studies in diet-induced obesity models suggested that there may be some central "set point" for the regulation of body weight that is genetically predetermined but expressed only in the presence of appropriate dietary exposure (19,20). Altered NPY regulation in the hypothalamus may be a characteristic feature, and the NPY system can respond both to the metabolic needs of the animals and the palatability of the food (20). Our model may thus be particularly useful for the study of diet-induced obesity, which is seen in most human obesity and diabetes.


   RESEARCH DESIGN AND METHODS
TOP
 ABSTRACT
 INTRODUCTION
 RESEARCH DESIGN AND METHODS
REFERENCES
 
Generation of transgenic mice.
We generated mice (homozygous) that overexpress mouse NPY exclusively in the central nervous system (7). We used a 3.6-kb human Thy-1 DNA spanning the 5'-flanking region containing the first intron (21), which is a major component of the surface of mature neurons in the brain. The DNA fragment (Thy-1-NPY cDNA) was microinjected into the pronuclei of fertilized eggs obtained from BDF1 female mice using standard techniques, as previously reported (7,22).

Northern blot analysis.
Total RNA was extracted from the whole brain of experimental animals using the Ultraspec-II RNA extraction system (Bioteck, Houston, TX). The concentration of RNA was measured using the absorbance at 260 nm. For Northern blot analysis, RNA (20 µg) was denatured in a solution containing 2.2 mmol/l formaldehyde and 50% formamide (vol/vol) by heating at 55°C for 15 min. Aliquots of total RNA were then size-fractionated in a 1.2% agarose/formaldehyde gel (23). Ethidium bromide staining was used to identify the position of the 18S and 28S rRNA subunits and to confirm that equivalent amounts of undegraded RNA had been loaded. The fractionated RNA was transferred to a Hybond-N membrane (Amersham, Bucks, U.K.) and crosslinked by UV irradiation (Stratagene, La Jolla, CA).

The plasmid containing cDNA for NPY was supplied by Dr. Steven L. Sabol (National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD). The plasmid containing cDNA of Y-1 and Y-5 was obtained from Dr. Herbert Herzog (The Garvan Institute of Medical Research, Sydney, Australia), and the ß-actin cDNA was from Dr. S.S. Liu (Department of Microbiology and Immunology, National Cheng Kung University, Taiwan City, Taiwan, China). Probes were labeled with [{alpha}-32P]dCTP using the Megaprime labeling system kit (Amersham). Hybridizations were carried out in medium containing denatured salmon sperm DNA (100 µg/ml) at 65°C for 2 h. The membrane was washed twice for 20 min in 2 x sodium saline citrate (SSC)/0.1% SDS at room temperature and once for 20 min in 0.1 x SSC/0.1% SDS at 40°C. Autoradiograms were prepared on Kodak X-ray film (Rochester, NY) using a single enhancing screen at –70°C (laid down for 16 h). Intensity of the mRNA bands on the blot was quantified by scanning densitometry (Hoefer, San Francisco, CA). The response of ß-actin was used as an internal standard.

NPY expression was examined twice (in the 12th and 64th week of each mouse’s life), and the animals were killed at 10:00 A.M. by cervical dislocation. Essentially, the same results were obtained in each study and the latter data were presented.

Behavioral analysis.
Transgenic mice (male) were housed per group in a regulated environment (22 ± 2°C, 55 ± 10% humidity, and 12-h light-dark cycle). The cumulative food intake of NPY-overexpressing and control mice was measured every 3 weeks before and after the start of 50% sucrose–loaded powder diet. Experiments were performed beyond 1 year.

NPY receptor antagonist experiments.
We examined the effect of the selective NPY receptor antagonists on food intake induced by 50% sucrose–loading in NPY-overexpressing mice. For intra–third cerebroventricular (ICV) injection, the mice (11 weeks of age) were anesthetized with sodium pentobarbital (80–85 mg/kg i.p.) and placed in a stereotaxic instrument (SR-6; Narishige, Tokyo) 7 days before the experiments. A hole was made in each skull by using a needle inserted 0.9 mm lateral to the central suture and 0.9 mm posterior to the bregma. A 24-gauge cannula beveled at one end over a distance of 3 mm (Safelet-Cas; Nipro, Osaka, Japan) was implanted into the third cerebral ventricle for ICV injection. The cannula was fixed to the skull with dental cement and capped with silicon without an obtruder. A 27-gauge injection insert was attached to a microsyringe by PE-20 tubing. Using tweezers, this could easily be inserted into a fixed cannula without holding the mouse and thus without greatly disturbing the animal’s behavior. After completion of the experiment, the location of the cannula tip was confirmed by dye injection (Evans blue 0.5% and Zelatin 5%) and histological examination of frozen brain sections (24).

NPY-overexpressing and control mice at 12 weeks of age were fed on 50% sucrose–loaded powder diet after implantation. Cumulative food intake was measured before and after ICV injection of NPY Y-1 and Y-5 receptor antagonists. BIBO3304 was supplied by Boeringer-Ingelheim Pharma (Grenzach-wyhlen, Germany), and L-152,804 was from Banyu Pharmaceutical (Tokyo). Just before administration, each drug was diluted in 4 µl of artificial cerebrospinal fluid, which also served as the control solution, and ICV was administered at a dose of 2 nmol/mouse every 12 h. The dosage of the antagonists was chosen based on our previous study (25) to rule out potential nonspecific effects.

Energy expenditure.
Oxygen consumption was determined with an O2/CO2 metabolism–measuring system (model MK-5,000; Muromachikikai, Tokyo) at 25°C in nine transgenic and nine control mice. The chamber volume was 560 ml, and airflow to the chamber was 500 ml/min; samples were taken every 3 min, and a standard gas reference was taken every 30 min. Mice were kept unrestrained in the chamber without food or water during the light cycle, and oxygen consumption was measured for 2 h. Essentially, the same results were obtained in the 12th and 60th weeks of the animals’ lives, and the latter data were presented.

Glucose tolerance.
Plasma glucose and insulin were measured four times in nonfasting conditions. Oral glucose tolerance (2 g/kg body wt) was performed at 64 weeks, and AUC for glucose was determined. Plasma glucose and insulin were determined by Glucose B test (Wako, Osaka, Japan) and enzyme-linked immunosorbent assay insulin kit (Morinaga, Tokyo), respectively.


   ACKNOWLEDGMENTS
 
This study was supported in part by Grants-in-Aid for Scientific Research (09671057), Developmental Scientific Research (08559012), and International Scientific Research (80168418) from the Ministry of Education, Science, Sports, and Culture of Japan (to A.I.).

The authors sincerely thank Dr. Steven L. Sabol (National Heart, Lung, and Blood Institute, National Institutes of Health) and Dr. Herbert Herzog (The Garvan Institute of Medical Research) for kindly supplying us the plasmid containing cDNA for NPY and for Y-1 and Y-5 receptors, respectively.


   FOOTNOTES
 
Address correspondence and reprint requests to Akio Inui, MD, Associate Professor, Second Department of Internal Medicine, Kobe University School of Medicine, 7-5-2 Kusunoki-cho, Chuo-ku, Kobe 650-0017, Japan. E-mail: inui{at}med.kobe-u.ac.jp.

Received for publication 16 March 2000 and accepted in revised form 16 January 2001.

AUC, area under curve; ICV, intra–third cerebroventricular; NPY, neuropeptide Y; SSC, sodium saline citrate.


   REFERENCES
TOP
 ABSTRACT
 INTRODUCTION
 RESEARCH DESIGN AND METHODS
 REFERENCES
 

  1. Woods SC, Seeley RJ, Porte D Jr, Schwartz MW: Signals that regulate food intake and energy homeostasis. Science 280:1378–1383, 1998[Abstract/Free Full Text]
  2. Inui A: Feeding and body-weight regulation by hypothalamic neuropeptides–mediation of the actions of leptin. Trends Neurosci 22:62–67, 1999[Medline]
  3. Kalra SP, Dube MG, Pu S, Xu B, Horvath TL, Kalra PS: Interacting appetite-regulating pathways in the hypothalamic regulation of body weight. Endocr Rev 20:68–100, 1999[Abstract/Free Full Text]
  4. Elmquist JK, Elias CP, Saper CB: From lesions to leptin: hypothalamic control of food intake and body weight. Neuron 22: 221–232, 1999
  5. Inui A: Transgenic approach to the study of body weight regulation. Pharmacol Rev 52:35–62, 2000[Abstract/Free Full Text]
  6. Zarjevski N, Cusin I, Vettor R, Rohner-Jeanrenaud F, Jeanrenaud B: Chronic intracerebroventricular neuropeptide-Y administration to normal rats mimics hormonal and metabolic changes of obesity. Endocrinology 133:1753–1758, 1993[Abstract]
  7. Inui A, Okita M, Nakajima M, Momose K, Ueno N, Teranishi A, Miura M, Hirosue Y, Sano K, Sato M, Watanabe M, Sakai T, Watanabe T, Ishida K, Silver J, Baba S, Kasuga M: Anxiety-like behavior in transgenic mice with brain expression of neuropeptide Y. Proc Assn Am Physicians 110:171–182, 1998[Medline]
  8. Erickson JC, Clegg KE, Palmiter RD: Sensitivity to leptin and susceptibility to seizures of mice lacking neuropeptide Y. Nature 381:415–418, 1996[Medline]
  9. Thiele TE, Marsh DJ, Ste-Marlie L, Bernstein IL, Palmiter RD: Ethanol consumption and resistance are inversely related to neuropeptide Y levels. Nature 396:366–369, 1998[Medline]
  10. Inui A: Neuropeptide Y feeding receptors: are multiple subtypes involved? Trends Pharmacol Sci 20:43–46, 1999[Medline]
  11. Gerald C, Walker MW, Criscione L, Gustafson EL, Batzl-Hartmann C, Smith KE, Vaysse P, Durkin MM, Laz TM, Linemeyer DL, Schaffhauser AO, Whitebread S, Hofbauer KG, Taber RI, Branchek TA, Weinshank RL: A receptor subtype involved in neuropeptide Y-induced food intake. Nature 382:168–171, 1996[Medline]
  12. Xu B, Kalra PS, Moldawer LL, Kalra SP: Increased appetite augments hypothalamic NPY Y1 receptor gene expression: effects of anorexigenic ciliary neurotropic factor. Regul Pept 75–76:391–395, 1998
  13. Xin XG, Huang XF: Down-regulated NPY receptor subtype-5 mRNA expression in genetically obese mouse brain. Neuroreport 9:737–741, 1998[Medline]
  14. Widdowson PS: Regionally-selective down-regulation of NPY receptor subtypes in the obese Zucker rat: relationship to the Y5 ‘feeding’ receptor. Brain Res 758:17–25, 1997[Medline]
  15. Thorsell A, Michalkiewicz M, Dumont Y, Quirion R, Caberlotto L, Rimondini R, Mathé AA, Heilig M: Behavioral insensitivity to restraint stress, absent fear suppression of behavior and impaired spatial learning in transgenic rats with hippocampal neuropeptide Y overexpression. Proc Natl Acad Sci U S A 97:12852–12857, 2000[Abstract/Free Full Text]
  16. Pedrazzini T, Seydoux J, Kunstner P, Aubert JF, Grouzmann-E; Beermann F, Brunner HR: Cardiovascular response, feeding behavior and locomotor activity in mice lacking the NPY Y1 receptor. Nat Med 4:722–726, 1998[Medline]
  17. Marsh DJ, Hollopeter G, Kafer KE, Palmiter RD: Role of the Y5 neuropeptide Y receptor in feeding and obesity. Nat Med 4:718–721, 1998[Medline]
  18. Naveilhan P, Hassani H, Canals JM, Ekstrand AJ, Larefalk A, Chhajlani V, Arenas E, Gedda K, Svensson L, Thoren P, Ernfors P: Normal feeding behavior, body weight and leptin response require the neuropeptide Y Y2 receptor. Nat Med 5:1188–1193, 1999[Medline]
  19. Levin BE, Keesey RE: Defense of differing body weight set points in diet-induced obese and resistant rats. Am J Physiol 274:R412–R419, 1998[Abstract/Free Full Text]
  20. Levin BE: Arcuate NPY neurons and energy homeostasis in diet-induced obese and resistant rats. Am J Physiol 276:R382–R387, 1999[Abstract/Free Full Text]
  21. Gordon JW, Chesa PG, Nishimura H: Regulation of Thy-1 gene expression in transgenic mice. Cell 50:445–452, 1987[Medline]
  22. Ueno N, Inui A, Iwamoto M, Kaga T, Asakawa A, Okita M, Fujimiya M, Nakajima Y, Ohmoto Y, Ohnaka M, Nakaya Y, Miyazaki J, Kasuga M: Decreased food intake and body weight in pancreatic polypeptide-overexpressing mice. Gastroenterology 17:1427–1432, 1999
  23. Lehrach H, Diamond D, Wozney JM, Boedtker H: RNA molecular weight determinations by gel electrophoresis under denaturing conditions, a critical reexamination. Biochemistry 16:4743–4751, 1977[Medline]
  24. Nakajima M, Inui A, Teranishi A, Miura M, Hirosue Y, Okita M, Himori N, Baba S, Kasuga M: Effects of PP family peptides on feeding and learning behavior in mice. J Pharmacol Exp Ther 268:1010–1014, 1994[Abstract/Free Full Text]
  25. Asakawa A, Inui A, Kaga T, Yuzuriha H, Nagata T, Ueno N, Makino S, Fujimiya M, Niijima A, Fujino MA, Kasuga M: Ghrelin is an appetite-stimulatory signal from stomach with structural resemblance to motilin. Gastroenterology 120:337–345, 2001[Medline]

Add to CiteULike CiteULike   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 Endocr. Rev.Home page
M. M. Kamiji and A. Inui
Neuropeptide Y Receptor Selective Ligands in the Treatment of Obesity
Endocr. Rev., October 1, 2007; 28(6): 664 - 684.
[Abstract] [Full Text] [PDF]

Home page
 FASEB J.Home page
A. INUI, A. ASAKAWA, C. Y. BOWERS, G. MANTOVANI, A. LAVIANO, M. M. MEGUID, and M. FUJIMIYA
Ghrelin, appetite, and gastric motility: the emerging role of the stomach as an endocrine organ
FASEB J, March 1, 2004; 18(3): 439 - 456.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Endocrinol. Metab.Home page
S. C. Chua Jr., S. M. Liu, Q. Li, A. Sun, W. F. DeNino, S. B. Heymsfield, and X. E. Guo
Transgenic complementation of leptin receptor deficiency. II. Increased leptin receptor transgene dose effects on obesity/diabetes and fertility/lactation in lepr-db/db mice
Am J Physiol Endocrinol Metab, March 1, 2004; 286(3): E384 - E392.
[Abstract] [Full Text]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kaga, T.
Right arrow Articles by Cheng, J.-T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kaga, T.
Right arrow Articles by Cheng, J.-T.
Social Bookmarking
Add to CiteULike   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Diabetes Diabetes Care Clinical Diabetes Diabetes Spectrum